Compare UHG & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UHG | PLRX |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | 195 | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.8M | 81.1M |
| IPO Year | N/A | 2020 |
| Metric | UHG | PLRX |
|---|---|---|
| Price | $1.19 | $1.30 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.67 |
| AVG Volume (30 Days) | 79.1K | ★ 415.1K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.99 | $1.09 |
| 52 Week High | $4.78 | $1.95 |
| Indicator | UHG | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 40.93 | 51.16 |
| Support Level | $1.15 | $1.12 |
| Resistance Level | $1.81 | $1.36 |
| Average True Range (ATR) | 0.02 | 0.07 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 77.78 | 68.75 |
United Homes Group Inc designs, builds and sells homes in high growth markets, including South Carolina, North Carolina, and Georgia. UHG employs a land-light operating, with a focus on the design, construction and sale of entry-level, first, second and third move-up single-family houses. The company principally builds detached single-family houses, and, to a lesser extent, attached single-family houses, including duplex houses and town houses. The company has three reportable segments: GSH South Carolina, Rosewood, and Other.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.